Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TRVI | Performance Stock Options (right to buy) | Award | $0 | +128K | $0.00 | 128K | Jun 29, 2022 | Common Stock | 128K | $3.21 | Direct | F1 |
Id | Content |
---|---|
F1 | Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 160,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. On June 29, 2022, the Compensation Committee of the Board of Directors of the Issuer certified that certain performance metrics related to the successful results of the PRISM trial were satisfied, resulting in the vesting of the option as to 128,000 shares of common stock. The performance-based option remains eligible for vesting with respect to the remaining shares of common stock underlying the option in the event that additional performance metrics related to the successful results of the CANAL trial are satisfied. |